A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
About This Trial
This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at sixteen study visits over three years. Nasal swab and stool samples will also be collected from participants at seven time-points across the study period. The study is not designed to assess safety or tolerability of the influenza vaccines administered as part of this study.
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
Flu Vaccine (Year 1)
Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
Flu Vaccine (Year 2)
Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
Flu Vaccine (Year 3)
Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.